Form 4: Pulmonx COO/CFO Sung Receives Significant Equity Grant

Pulmonx Corp's Chief Operating Officer and Chief Financial Officer, Derrick Sung, was granted 1.2 million Restricted Stock Units and 400,000 Performance Stock Units, effective December 1, 2025.

Summary

• Derrick Sung, the Chief Operating Officer and Chief Financial Officer of Pulmonx Corp (LUNG), received an equity grant on December 1, 2025.
• The grant includes 1,200,000 Restricted Stock Units (RSUs) and 400,000 Performance Stock Units (PSUs).
• The RSUs vest 25% one year from the grant date, with the remainder vesting in equal quarterly installments over the subsequent three-year period.
• The PSUs are contingent rights to receive common stock, vesting upon meeting two conditions: (a) the Issuer's common stock achieving a specified price per share, and (b) 33% vesting one year from the grant date, with the remainder in eight equal quarterly installments.
• Following these transactions, Sung beneficially owns 1,335,319 shares of common stock.

Sentiment

Score: 7

Explanation: The filing indicates a significant equity grant to a key executive, which is generally positive for aligning management incentives with shareholder interests and executive retention. The performance-based component of the PSUs further strengthens this alignment. However, it is a routine compensation disclosure and does not directly reflect operational or financial performance.

Positives

• A significant equity grant to a key executive, Derrick Sung, aligns management's interests with long-term shareholder value.
• The performance-based vesting for Performance Stock Units (PSUs) incentivizes stock price appreciation, directly linking executive reward to market performance.
• The multi-year vesting schedules for both RSUs and PSUs serve as a strong retention mechanism for key talent.

Negatives

• The equity grants have no immediate cash value for the executive; their ultimate value is contingent on future stock performance and successful vesting.
• The conversion of these units into common stock upon vesting could lead to minor dilution for existing shareholders.

Risks

• The value of the equity grants is directly tied to the future performance of Pulmonx Corp's common stock, which is subject to market fluctuations and company-specific factors.
• Performance Stock Units (PSUs) are contingent on the Issuer's common stock achieving a specified price per share, a condition that may not be met.
• The multi-year vesting schedules mean the executive's full benefit from these grants is not guaranteed and depends on continued employment and company performance over time.

Future Outlook

The grant of Performance Stock Units (PSUs) indicates a forward-looking incentive structure tied to the company's future stock price performance and continued service of the executive. The multi-year vesting schedules for both RSUs and PSUs suggest an expectation of long-term executive commitment and value creation.

Management Comments

• Represents grant of Restricted Stock Units payable solely in common stock of the Issuer, 25% of which vests one year from the grant date of December 1, 2025, and the remainder vests in equal quarterly installments over the three-year period following the date of grant.
• Each Performance Stock Unit represents a contingent right to receive one share of the Issuer's common stock. The Performance Stock Units vest upon meeting the following two conditions: (a) upon the Issuer's common stock achieving a specified price per share and (b) with respect to 33% on the one year following the grant date of December 1, 2025 and the remainder in eight equal quarterly installments.

Industry Context

Equity grants, particularly those combining time-based (RSUs) and performance-based (PSUs) vesting, are a common practice in the biotechnology and medical device industries for executive compensation. This structure aims to attract, retain, and motivate key executives by aligning their financial incentives with the long-term success and shareholder value creation of the company, especially in sectors with high growth potential and significant R&D investment like Pulmonx.

Comparison to Industry Standards

• The use of both Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) is a standard practice in executive compensation packages across the medical technology and growth-oriented sectors, similar to companies like Intuitive Surgical or Medtronic, which often use a mix of equity incentives to align executive interests with long-term shareholder value.
• The vesting schedule, with a one-year cliff followed by quarterly installments over three years for RSUs, is typical for executive retention and long-term incentive plans.
• The inclusion of a stock price target for PSU vesting is a common mechanism to directly link executive compensation to market performance, a strategy employed by many publicly traded companies to incentivize aggressive growth and shareholder returns.

Related Party Transactions

• Grant of 1,200,000 Restricted Stock Units and 400,000 Performance Stock Units to Derrick Sung, the Chief Operating Officer and Chief Financial Officer of Pulmonx Corp, constitutes a related party transaction as it involves compensation to an executive officer.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through incentivized management performance; potential for minor dilution upon vesting of equity awards.
• Employees: May signal stability and confidence in executive leadership; could set a precedent for future executive compensation structures.
• Management (Derrick Sung): Significant long-term incentive and wealth creation opportunity tied to company performance.

Next Steps

• Vesting of 25% of RSUs one year from December 1, 2025, with subsequent quarterly vesting over three years.
• Vesting of 33% of PSUs one year from December 1, 2025, with subsequent quarterly vesting over eight installments, contingent on achieving a specified stock price.

Key Dates

Keywords

Pulmonx, LUNG, SEC Form 4, Restricted Stock Units, Performance Stock Units, Executive Compensation, Derrick Sung, Equity Grant, Corporate Governance, Stock Options